Eli Lilly studying experimental therapy for Alzheimer’s


INDIANA (WEHT) – Eli Lilly is in the middle of a larger study for its experimental anti-body therapy for Alzheimer’s.

In March, the company released phase-two results which were focused on early-stage patients. It showed 68 percent of people in the trial had a decrease in amyloid plaque, which can cause cognitive decline.

Once the larger study is complete, Eli Lilly plans to send the drug to the FDA for approval.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Stories